



ASX ANNOUNCEMENT

Friday 9 August 2024

IDT Secures New Contract with Sanofi Australia

IDT Australia Limited (ASX: IDT) (IDT or the **Company**) is pleased to announce that it has secured a follow-on contract with Sanofi Australia (**Sanofi**) worth between \$2.5 million and \$4 million for the preclinical formulation, development and manufacture of Sanofi's messenger RNA (**mRNA**) technology for its translational clinical program.

The contract comes on the back of IDT being awarded a Master Service Agreement (**MSA**) with Sanofi, which was announced on 16 April 2024. The MSA provides flexibility for Sanofi to choose services from IDT and allows for follow-on work packages.

Ends.../

Authorised by the Board of Directors of IDT Australia Limited.

For investor and media enquiries, please contact:

Brendon Lau

E: brendon@vantagepointpartners.com.au

M: +61 409 341 613

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on IDT Australia's beliefs, assumptions, and expectations and on information currently available to IDT Australia.

All statements that address operating performance, events, or developments that IDT Australia or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of IDT Australia or the market it operates in.

IDT Australia believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. IDT Australia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of IDT Australia or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.